Stoke Therapeutics Inc. (STOK)
Stoke Therapeutics Inc. (STOK) Stock Price, Analysis & Data
| Bid | 23.62 |
| Market Cap | 2.1B |
| Revenue (ttm) | 27.59M |
| Net Income (ttm) | -207.9M |
| Beta | 1.23 |
| EPS (ttm) | -3.39 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.31 |
| P/B (ttm) | 5.88 |
| P/S (ttm) | 76.12 |
| Earnings Date | Nov 3, 2026 |
| Ask | 33.3 |
| Volume | 145,479 |
| Avg. Volume (20D) | 812,246 |
| Open | 33.28 |
| Previous Close | 32.97 |
| Day's Range | 32.31 - 33.28 |
| 52-Week Range | 15.50 - 40.22 |
| Analyst | Strong Buy |
| Price Target | 46 (41.32%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About STOK
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy...
Financial Performance
In 2025, Stoke Therapeutics's revenue was 184.42M, an increase of 404.5% compared to the previous year's 36.55M. Earnings were -6.88M, a decrease of -92.26%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for STOK stock is "Strong Buy". The 12-month stock price forecast is 46, which is upside of 41.32% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
